Finland· FI-REL-REL53954
Aimovig
A erenumab product containing erenumab, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Erenumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Erenumab · ATC N02CD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Erenumab
- Manufacturer
- Novartis Europharm Limited
- Country
- Finland (FI)
- ATC code
- N02CD01
- ATC class
- Erenumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Erenumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAIMOVIGAmgen, Inc
- CzechiaAIMOVIGNovartis Europharm Limited, Dublin
- BelgiumAimovig 140 mgNovartis Europharm
- IcelandAimovigNovartis Europharm Limited*
- NetherlandsAimovig 140 mg oplossing voor injectie in voorgevulde penNovartis Europharm Limited
- SwedenAimovig 140 mg Injektionsvätska, lösning i förfylld injektionspennaNovartis Europharm Limited
- SpainAIMOVIG 140 MG SOLUCIÓN INYECTABLE EN PLUMA PRECARGADANovartis Europharm Limited
- NorwayAimovigNovartis Europharm Limited (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aimovig
- Liechtenstein · Aimovig
- Norway · Aimovig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f026f5b0-22dc-4c76-a7d1-19a586b6c772 GET /v1/drugs/f026f5b0-22dc-4c76-a7d1-19a586b6c772?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "2.5",
"form": "injektioneste, liuos, esitäytetty kynä",
"route": "Ihon alle",
"ddd_unit": "mg",
"strength": "140 mg",
"atc_label": "erenumabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/18/1293/004-005",
"fimea_rel_id": "REL53954",
"authorised_at": "2019-04-26"
}See everything about erenumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.